Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.
1. A compound of Formula I:
wherein
A is —SO 2 —;
B is —NH—;
Ring C is a 5 or 6 membered heteroaryl or heterocyclic ring, or a 6 membered aryl ring;
E 1 , E 2 , and E 3 are independently selected from C, CH, and N, wherein one of E 1 , E 2 , and E 3 may be absent;
R 1 and R 2 are independently selected from the group consisting of H, lower alkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, haloalkyl, carboxy, —CONH 2 , —CON— alkyl, nitrile, —S-alkyl, —O-alkyl, acyl, and oxo; or R 1 and R 2 with the atoms attached thereto combine to form a 5-6 membered fused aryl, heteroaryl, carbocyclic or heterocyclic ring D containing 0-3 heteroatoms, where Ring D may further be substituted at a position two atoms away from the juncture with Ring C;
R 3 is independently selected from the group consisting of H, lower alkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, haloalkyl, carboxy, —CONH 2 , —CON-alkyl, nitrile, —S-alkyl, —O-alkyl, acyl, and oxo;
R 4 is selected from the group consisting of H, OH, halogen, and lower alkyl;
each R 5 is hydrogen or taken together are oxo;
Y is selected from the group consisting of N and CH; and
X 1 , X 2 , X 3 , and X 4 are independently selected from the group consisting of CH, C—R 4 , and N; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
2. A compound selected from:
N-phenyl-4-(piperazin-1-yl)benzenesulfonamide;
N-isopropyl-4-((4-(piperazin-1-yl)phenyl)sulfonamido)benzamide;
N-methyl-4-((4-(piperazin-1-yl)phenyl)sulfonamido)benzamide;
N-(3,4-dimethylphenyl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(3,5-dimethylphenyl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(3,5-dichlorophenyl)-4-(piperazin-1-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)benzenesulfonamide;
N-(naphthalen-2-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(cinnolin-7-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(isoquinolin-7-yl)-4-(piperazin-1-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(quinolin-6-yl)benzenesulfonamide;
N-(cinnolin-6-yl)-4-(piperazin-1-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(quinoxalin-6-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(pyrido[2,3-b]pyrazin-7-yl)benzenesulfonamide;
N-(1H-benzo[d][1,2,3]triazol-5-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(2-methylbenzo[b]thiophen-5-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(benzo[c][1,2,5]thiadiazol-5-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(1H-indol-6-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(1H-indol-5-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(benzo[d]isoxazol-5-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(2-aminoimidazo[1,2-a]pyrimidin-6-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(2,3-dihydrobenzofuran-6-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(2,3-dihydrobenzofuran-5-yl)-4-(piperazin-1-yl)benzenesulfonamide;
N-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-4-(piperazin-1-yl)benzenesulfonamide;
2-hydroxy-N-phenyl-4-(piperazin-1-yl)benzenesulfonamide;
4-(2-oxopiperazin-1-yl)-N-phenylbenzenesulfonamide;
2-fluoro-4-(2-oxopiperazin-1-yl)-N-phenylbenzenesulfonamide;
N-phenyl-4-(piperazin-1-yl-2,2,6,6-d4)benzenesulfonamide;
N-phenyl-4-(piperidin-4-yl)benzenesulfonamide;
4-(piperidin-4-yl)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(pyridin-4-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(pyridin-3-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(pyridin-2-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(thiazol-2-yl)benzenesulfonamide;
4-(piperazin-1-yl)-N-(quinolin-7-yl)benzenesulfonamide;
N-phenyl-6-(piperazin-1-yl)pyridine-3-sulfonamide;
N-phenyl-5-(piperazin-1-yl)pyridine-2-sulfonamide;
N-(3,5-difluorophenyl)-4-(piperazin-1-yl)benzenesulfonamide;
3-fluoro-4-(piperazin-1-yl)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)benzenesulfonamide;
6-(piperazin-1-yl)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridine-3-sulfonamide;
5-(piperazin-1-yl)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridine-2-sulfonamide;
N-phenyl-4-(piperidin-4-yl)benzenesulfonamide; and
4-(piperidin-4-yl)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)benzenesulfonamide;
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
4. The pharmaceutical composition of claim 3 , wherein said pharmaceutical composition further comprises a second pharmaceutical drug compound.
5. The pharmaceutical composition of claim 4 , wherein said second pharmaceutical drug compound is selected from the group consisting of a statin, a cardiovascular drug, a metabolic drug, and an antihypertensive drug.
6. A method for reducing LDL levels in a mammal in need thereof by administering a pharmaceutical composition comprising a compound of claim 2 to said mammal.
7. A method for treating hypercholesterolemia in a mammal in need thereof by administering a pharmaceutical composition comprising a compound of claim 2 to said mammal.
8. A method of modulating low density lipoprotein receptor internalization in a plurality of hepatocyte cells, comprising:
inducing a conformational shift in
a PCSK9 protein, wherein said protein comprises a low density lipoprotein receptor binding site,
by binding a compound of Formula I of claim 1 to a binding site that induces allosteric modulation in the PCSK9 protein;
wherein the plurality of hepatocyte cells comprise low density lipoproteins
whereby the rate of low density lipoprotein receptor internalization by said plurality of hepatocytes is modulated by said conformational shift.
9. The method of claim 8 , whereby the rate of low density lipoprotein receptor internalization is increased.
10. A method of modulating a population of low density lipoprotein receptors in a plurality of hepatocyte cells, comprising:
inducing a conformational shift in
a PCSK9 protein, wherein said protein comprises a low density lipoprotein receptor binding site,
by binding a compound of Formula I of claim 1 to a binding site that induces allosteric modulation in the PCSK9 protein
whereby the population of said low density lipoprotein receptors is modulated by said conformational shift.
11. The method of claim 10 , whereby the population of low density lipoprotein receptors is increased.
12. A method for reducing LDL levels in a mammal in need thereof by administering a pharmaceutical composition comprising a compound of claim 1 to said mammal.
13. A method for treating hypercholesterolemia in a mammal in need thereof by administering a pharmaceutical composition comprising a compound of claim 1 to said mammal.